Form 4 for XYL Xylem Inc.
Accepted 2024-03-05 00:00:00 ET · period of report 2024-03-01 · accession 0001562180-24-002291 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-03-05 | 2024-03-01 | XYL | McShane Geri-Michelle | VP, CAO, Ctrl | A - Grant | $127.94 | +1,872 | 4,250 | +79% | +$239.5K |
| DM | 2024-03-05 | 2024-03-01 | XYL | McShane Geri-Michelle | VP, CAO, Ctrl | F - Tax | $127.94 | -759 | 3,491 | -18% | -$97.1K |
| D | 2024-03-05 | 2024-03-01 | XYL | McShane Geri-Michelle | VP, CAO, Ctrl | A - Grant | $127.94 | +1,884 | 1,884 | New | +$241.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-01 | A | A | 557 | $127.94 | 4,048 | D | — | — | (F5) Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one third increments on March 1, 2025, March 1, 2026 and March 1, 2027. |
| 2 | Common | Common Stock | 2024-03-01 | A | A | 814 | $127.94 | 3,749 | D | — | — | (F1) Reflects the acquisition of 814 shares of common stock upon vesting of performance-based stock units granted on March 1, 2021 under the Xylem Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to ROIC. |
| 3 | Common | Common Stock | 2024-03-01 | A | A | 501 | $127.94 | 4,250 | D | — | — | (F2) Reflects the acquisition of 501 shares of common stock earned upon vesting of performance-based restricted stock units granted on March 1, 2021 under the Xylem Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Total Shareholder Return. |
| 4 | Common | Common Stock | 2024-03-01 | F | D | 516 | $127.94 | 3,734 | D | — | — | (F3) Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of performance-based stock units granted on March 1, 2021 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February, 24, 2016). |
| 5 | Common | Common Stock | 2024-03-01 | F | D | 243 | $127.94 | 3,491 | D | — | — | (F4) Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of restricted stock units granted on March 1, 2021 (74), March 1, 2022 (87), and March 1, 2023 (82) under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016). |
| 6 | Derivative | Stock Options (Right to buy) | 2024-03-01 | A | A | 1,884 | $127.94 | 1,884 | D | $127.94 · — to 2034-03-01 | 1,884 Common Stock | (F6) Reflects an award of non-qualified stock options pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one-third increments on March 1, 2025, March 1, 2026 and March 1, 2027. |